血必净注射液与西维来司他钠对急性肺损伤/急性呼吸窘迫综合征大鼠保护作用的比较研究
该研究将71只雄性SD大鼠随机分为空白对照组(n=8)、ALI/ARDS模型组(n=21)、血必净注射液组(n=21)和西维来司他钠组(n=21),除空白对照组外均经尾静脉注射25 mg/kg脂多糖建立ALI/ARDS模型。建模后空白对照组和模型组腹腔注射等体积生理盐水每日2次;血必净组尾静脉注射血必净注射液8 mL/kg每日2次;西维来司他钠组腹腔注射西维来司他钠100 mg/kg每日3次,均连续给药5天。结果显示,与模型组相比,血必净组和西维来司他钠组支气管肺泡灌洗液中白细胞计数、中性粒细胞百分比、白细胞介素-6水平均显著降低,淋巴细胞百分比显著升高(均P<0.05),但两治疗组间上述指标无显著差异(均P>0.05)。实验结束时血必净组生存率52.4%(11/21)高于西维来司他钠组28.6%(6/21)和模型组14.3%(3/21),西维来司他钠组高于模型组,但差异均无统计学意义(P>0.05)。血必净组实验结束时体重及体重增长率高于西维来司他钠组[体重(g):217.1±6.4 vs. 207.1±7.0,体重增长率:(-0.9±2.8)% vs.(-4.3±3.5)%],两组间差异均无统计学意义(均P>0.05)。肺组织病理显示模型组肺泡内有大量炎性渗出物和炎性细胞浸润,伴局部肺泡上皮细胞及肺泡结构损伤,而血必净组和西维来司他钠组上述组织学改变均减轻。结论认为血必净注射液
要点
- 在脂多糖诱导的ALI/ARDS大鼠模型中,血必净注射液(尾静脉8 mL/kg每日2次)与西维来司他钠(腹腔注射100 mg/kg每日3次)均连续给药5天,两者均能显著降低支气管肺泡灌洗液白细胞计数、中性粒细胞百分比和白细胞介素-6水平,并升高淋巴细胞百分比(均P<0.05)。
- 两治疗组间上述炎症指标均无显著差异(均P>0.05),提示两者抗炎保护作用基本一致。
- 实验结束时生存率:血必净组52.4%(11/21) vs. 西维来司他钠组28.6%(6/21) vs. 模型组14.3%(3/21),血必净组高于西维来司他钠组和模型组,西维来司他钠组高于模型组,但差异均无统计学意义(P>0.05)。
- 实验结束时体重:血必净组217.1±6.4 g vs. 西维来司他钠组207.1±7.0 g;体重增长率:血必净组(-0.9±2.8)% vs. 西维来司他钠组(-4.3±3.5)%,两组间差异均无统计学意义(均P>0.05)。
- 肺组织病理显示模型组肺泡内有大量炎性渗出物和炎性细胞浸润,伴局部肺泡上皮细胞及肺泡结构损伤,血必净组和西维来司他钠组上述组织学改变均减轻。
适用人群与场景
- 雄性Sprague-Dawley(SD)大鼠,经尾静脉注射25 mg/kg脂多糖建立ALI/ARDS模型。
处置流程与药物剂量
- 空白对照组和ALI/ARDS模型组:腹腔注射等体积生理盐水,每日2次,连续5天。
- 血必净注射液组:尾静脉注射血必净注射液8 mL/kg,每日2次,连续5天。
- 西维来司他钠组:腹腔注射西维来司他钠100 mg/kg,每日3次,连续5天。
研究设计与关键结果
- 研究类型:动物实验;样本量:71只雄性SD大鼠,随机分为空白对照组(n=8)、ALI/ARDS模型组(n=21)、血必净注射液组(n=21)和西维来司他钠组(n=21)。
- 与ALI/ARDS模型组相比,血必净组和西维来司他钠组支气管肺泡灌洗液白细胞计数[(×10⁹/L):55.86±6.68、49.96±6.76 vs. 73.13±7.35]、中性粒细胞百分比(0.459±0.077、0.315±0.047 vs. 0.709±0.067)均显著降低(均P<0.05),淋巴细胞百分比(0.412±0.067、0.517±0.051 vs. 0.232±0.057)显著升高(均P<0.05),白细胞介素-6水平(ng/L:295.2±39.7、281.9±33.1 vs. 469.6±77.0)降低。
- 血必净组与西维来司他钠组上述指标比较均无显著差异(均P>0.05)。
- 实验结束时生存率:血必净组52.4%(11/21) vs. 西维来司他钠组28.6%(6/21) vs. ALI/ARDS模型组14.3%(3/21),血必净组高于西维来司他钠组和模型组,西维来司他钠组高于模型组,但差异均无统计学意义(P>0.05)。
- 实验结束时体重:血必净组217.1±6.4 g vs. 西维来司他钠组207.1±7.0 g;体重增长率:血必净组(-0.9±2.8)% vs. 西维来司他钠组(-4.3±3.5)%,两组间差异均无统计学意义(均P>0.05)。
- 肺组织病理:ALI/ARDS模型组肺泡内有大量炎性渗出物和炎性细胞浸润,伴局部肺泡上皮细胞及肺泡结构损伤;血必净组和西维来司他钠组上述组织学改变均减轻。
证据类型、等级与局限
- 证据类型:动物实验(大鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为动物实验,结果提示血必净注射液与西维来司他钠在脂多糖诱导的ALI/ARDS大鼠中抗炎保护作用基本一致,血必净组实验结束时生存率52.4%(11/21)高于西维来司他钠组28.6%(6/21),但差异无统计学意义(P>0.05)。
- 原文结论认为血必净注射液可通过抑制炎症减轻ALI/ARDS所致肺损伤和全身损害、改善大鼠生存,其保护作用与西维来司他钠基本一致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the protective effect of Xuebijing injection versus Sivelestat sodium on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) rats.
METHODS: A total of 71 male Sprague-Dawley (SD) rats were randomly divided into the blank control group (n = 8), ALI/ARDS model group (n = 21), Xuebijing injection group (n = 21) and Sivelestat sodium group (n = 21). Rats in the blank control group were injected with normal saline while the other three groups were intravenously injected 25 mg/kg lipopolysaccharide (LPS) via the tail vein to establish ALI/ARDS model. After induction of ALI/ARDS model, the blank control group and ALI/ARDS model group were given intraperitoneal injection of an equal volume of normal saline twice a day. Rats in the Xuebijing injection group were given tail vein injection of 8 mL/kg Xuebijing injection twice a day, and those in the Sivelestat sodium group were given intraperitoneal injection of 100 mg/kg Sivelestat sodium three times a day. All rats were administered continuously for five days. During the experiment, the general status of rats was observed, and the weight and survival were recorded. At the end of the experiment, bronchoalveolar lavage fluid (BALF) of rats was collected for the detection of inflammatory cells and inflammatory factors. Histopathological changes of rats lung tissue were observed.
RESULTS: Compared with the ALI/ARDS model group, the Xuebijing injection group and Sivelestat sodium group had significantly decreased white blood cell (WBC) count and percent of neutrophil (NEU%) [WBC (×109/L): 55.86±6.68, 49.96±6.76 vs. 73.13±7.35, NEU%: 0.459±0.077, 0.315±0.047 vs. 0.709±0.067, all P < 0.05], significantly increased percent of lymphocytes (LYM%: 0.412±0.067, 0.517±0.051 vs. 0.232±0.057, both P < 0.05), and reduced interleukin-6 (IL-6) level (ng/L: 295.2±39.7, 281.9±33.1 vs. 469.6±77.0) in BALF. However, there were no significant differences in these parameters between the Xuebijing injection group and Sivelestat sodium injection group (all P > 0.05). Survival rate at the end of experiment was higher in the Xuebijing group than that in the Sivelestat sodium injection group and ALI/ARDS model group [52.4% (11/21) vs. 28.6% (6/21), 14.3% (3/21)], and survival rate at the end of experiment was higher in the Sivelestat sodium injection group than that in the ALI/ARDS model group, but the differences were not statistically significant (P > 0.05). In addition, weight and weight growth rate in the Xuebijing injection group were higher than the Sivelestat sodium group at the end of the experiment [weight (g): 217.1±6.4 vs. 207.1±7.0, weight growth rate: (-0.9±2.8)% vs. (-4.3±3.5)%], there were no significant difference between the two groups (both P > 0.05). Lung histopathology in the ALI/ARDS model group revealed high level of inflammatory exudate and inflammatory cells infiltrated in the alveoli of rats, along with damage of local alveolar epithelial cell and alveolar structure. However, these histological changes were improved in the Xuebijing injection group and in the Sivelestat sodium group.
CONCLUSIONS: Xuebijing injection can alleviate ALI/ARDS-induced lung injury and systemic damage and improve the survival of rats by inhibiting inflammation. The protective effect of Xuebijing injection is essentially consistent with that of Sivelestat sodium.
参考来源
- Tian W, Dong T. [Comparative study of the protective effect of Xuebijing injection and Sivelestat sodium on acute lung injury/acute respiratory distress syndrome rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36177927. doi:10.3760/cma.j.cn121430-20220401-00334
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。